THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED COLLABORATION & LICENSE...Collaboration & License Agreement • September 9th, 2019 • BioNTech SE • Biological products, (no disgnostic substances)
This Collaboration & License Agreement (this “Agreement”) is dated as of October 9th 2018 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and BioNTech RNA Pharmaceuticals GmbH, a German corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Collaboration License Agreement • July 28th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • New York
This side letter agreement (the “Side Letter Agreement”) relates to the Myovant/Pfizer Agreement, under which Myovant and Pfizer have agreed for Pfizer to have an exclusive option to obtain exclusive commercialization and promotion rights and related development rights for the Oncology Product(s) in the Oncology Field in the Pfizer Territory (each as defined therein), among other activities, in accordance with the terms of the Myovant/Pfizer Agreement. The Parties now wish to enter into this Side Letter Agreement to extend the time period within which Pfizer may exercise such exclusive option under Section 10.5 of the Agreement.
FIRST AMENDMENT TO THE AMENDED AND RESTATED COLLABORATION LICENSE AGREEMENT BETWEEN OSI PHARMACEUTICALS, INC. AND AVEO PHARMACEUTICALS, INC.Collaboration License Agreement • August 6th, 2010 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment (the “Amendment”) effective as of the last date set forth on the signature page hereof, by and between OSI Pharmaceuticals, Inc. (“OSI”) and AVEO Pharmaceuticals, Inc. (“AVEO”) amends the Amended and Restated Collaboration License Agreement between OSI and AVEO, dated July 16, 2009 (the “Agreement”).
ANDCollaboration & License Agreement • August 16th, 1999 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances)
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED UNIVERSITY OF PENNSYLVANIA...Collaboration & License Agreement • March 27th, 2023 • BioNTech SE • Biological products, (no disgnostic substances)
This Amendment No. 2 to the Collaboration & License Agreement (“Amendment No. 2 ”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), with offices located at Penn Center for Innovation, 3600 Civic Center Blvd, 9th Floor, Philadelphia, PA 19104-4310, and BioNTech SE, a German corporation (“Licensee”), having a place of business at An der Goldgrube 12, 55131 Mainz, Germany is effective December 22, 2021 (“Amendment No. 2 Effective Date”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
CHEF1 COLLABORATION & LICENSE AGREEMENTCollaboration & License Agreement • December 27th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This CHEF1 collaboration and license agreement (“Collaboration”), effective as of October 26, 2015 (“Effective Date”), is made by and between CMC ICOS BIOLOGICS, INC., a Washington corporation having its principal offices at 22021 20th Avenue S.E., Bothell, WA 98021 (“CMC ICOS”), and Harpoon Therapeutics, Inc. a California corporation having its principal offices at 3260 Bayshore Boulevard, Brisbane, CA 94005 (“Collaborator”).
Page 2 3. Funding of the Research Program. During the Amendment No. 2 Term, up to ($[***]) of the existing funding for the Original Research Program under the Agreement can be reallocated to fund the Targeting Research Plan upon mutual agreement of...Collaboration & License Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances)
COLLABORATION & LICENSE AGREEMENTCollaboration & License Agreement • April 16th, 2020 • Immatics B.V. • Texas
This COLLABORATION & LICENSE AGREEMENT (this “Agreement”) is entered into as of August 17, 2015 (the “Effective Date”) by and between IMMATICS US INC., a corporation organized and existing under the laws of Delaware (“Immatics US”) and The University of Texas M. D. Anderson Cancer Center, (“MD Anderson”), a member institution of The University of Texas System (“System”), with a place of business at 1515 Holcombe Blvd., Houston, Texas. Immatics US and MD Anderson are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION & LICENSE AGREEMENT DATED AS OF OCTOBER 9th, 2018Collaboration & License Agreement • February 9th, 2022
This Collaboration & License Agreement (this “Agreement”) is dated as of October 9th 2018 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and BioNTech RNA Pharmaceuticals GmbH, a German corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
Project Cardinal: Collaboration & License Agreement Concept SheetCollaboration & License Agreement • June 17th, 2021
This Concept Sheet is for preliminary discussion purposes only, and is not to be construed as a legally binding agreement or an offer or agreement to negotiate, execute or consummate the terms of any business transaction or to take any other action. Neither this Concept Sheet nor any course of conduct by either Party before or after the date of this Concept Sheet would give rise to any obligation on the part of either Party to (i) continue discussions or negotiations related to, or consummate, any transaction, or (ii) execute and deliver any definitive agreements related thereto. It is understood that execution of any definitive agreements is subject to, among other things, the completion of scientific, legal and commercial due diligence, the negotiation of definitive documentation and the approval of the transaction by each party’s Board of Directors. The definitive agreements, if entered into, would contain additional terms and conditions. The existence of this Concept Sheet, its con
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED UNIVERSITY OF PENNSYLVANIA...Collaboration & License Agreement • March 27th, 2023 • BioNTech SE • Biological products, (no disgnostic substances)
This Amendment No. 1 to the Collaboration & License Agreement (“Amendment”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), with offices located at Penn Center for Innovation, 3600 Civic Center Blvd, 9th Floor, Philadelphia, PA 19104-4310, and BioNTech SE, a German corporation (“Sponsor”), having a place of business at An der Goldgrube 12, 55131 Mainz, Germany is effective September 8, 2021 (“Amendment Effective Date”). Penn and Sponsor may be referred to herein as a “Party” or, collectively, as “Parties”.
COLLABORATION & LICENSE AGREEMENTCollaboration & License Agreement • December 5th, 2023 • Elevai Labs Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “License Agreement” or “Agreement”) is made and entered into as of the date of the last signature herein (the “Effective Date”), by and between Yuva Biosciences, Inc., a Delaware corporation with its principal place of business at 1500 First Avenue N, Suite L133, Birmingham, AL 35203 (“Yuva Bio”), and Elevai Labs, Inc., a Delaware corporation with its principal place of business at 1120 Newport Center Drive, Suite 250, Newport Beach, California 95618 (“ELEVAI”). In this Agreement, Yuva Bio and ELEVAI are collectively referred to as the “Parties” and each individually as a “Party”.
Collaboration & License Agreement Concept SheetCollaboration & License Agreement • July 16th, 2021
This Concept Sheet is for preliminary discussion purposes only, and is not to be construed as a legallybinding agreement or an offer or agreement to negotiate, execute or consummate the terms of any business transaction or to take any other action. Neither this Concept Sheet nor any course of conduct by either Party before or after the date of this Concept Sheet would give rise to any obligation on the part of either Party to (i) continue discussions or negotiations related to, or consummate, any transaction, or (ii) execute and deliver any definitive agreements related thereto. It is understood that execution of any definitive agreements is subject to, among other things, the completion of scientific, legal and commercial due diligence, the negotiation of definitive documentation and the approval of the transaction by each party’s Board of Directors. The definitive agreements, if entered into, would contain additional terms and conditions. The existence of this Concept Sheet, its cont
ConfidentialRiptide Aurinia Collaboration & License AgreementBetweenAurinia Pharmaceuticals Inc.andRiptide Bioscience, Inc. Effective Date: August 16, 2021Collaboration & License Agreement • August 17th, 2021 • Aurinia Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Riptide Aurinia Collaboration & License Agreement (the “Agreement”) is entered into as of August 16, 2021 (the “Effective Date”), by Aurinia Pharmaceuticals Inc., an Alberta corporation having offices at #1203-4464 Markham Street, Victoria, BC V8Z 7X8 Canada (“Aurinia”) and Riptide Bioscience, Inc., a corporation duly organized and existing under the laws of Delaware, having offices at 941 Railroad Avenue, Vallejo, California 94592 USA (“Riptide”). Both Aurinia and Riptide are referred to individually as a “Party” and collectively as the “Parties.”
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Collaboration License Agreement • October 26th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • New York
This side letter agreement (the “Side Letter Agreement”) relates to the Myovant/Pfizer Agreement, under which Myovant and Pfizer have agreed for Pfizer to have an exclusive option to obtain exclusive commercialization and promotion rights and related development rights for the Oncology Product(s) in the Oncology Field in the Pfizer Territory (each as defined therein), among other activities, in accordance with the terms of the Myovant/Pfizer Agreement. The Parties entered into a prior Side Letter Agreement, dated May 4, 2021, extending the time period within which Pfizer may exercise such exclusive option under Section 10.5 of the Agreement. The Parties now wish to enter into this Side Letter Agreement to further extend the time period within which Pfizer may exercise such exclusive option under Section 10.5 of the Agreement.
